We are live on ! Find out more
BOLD

Audentes Therapeutics, Inc
BOLD

Delisted

BOLD was delisted on the 14th of January, 2020.

Back to rankings

70 hedge funds and large institutions have $409M invested in Audentes Therapeutics, Inc in 2017 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 37 increasing their positions, 9 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

311% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 9

240% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 5

50% more capital invested

Capital invested by funds: $272M → $409M (+$137M)

21% more funds holding

Funds holding: 58 → 70 (+12)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
70
Holders Change
+12
Holders Change %
+20.69%
% of All Funds
1.75%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
17
Increased
37
Reduced
9
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$20.6M
2
PA
Perceptive Advisors
New York
+$11.2M
3
RG
Redmile Group
California
+$10.2M
4
BlackRock
BlackRock
New York
+$8.74M
5
Jennison Associates
Jennison Associates
New York
+$8.73M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$9.07M
2
VMI
VHCP Management II
New York
-$7.82M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.71M
4
CAM
Cormorant Asset Management
Massachusetts
-$1.62M
5
FCMI
Foresite Capital Management III
California
-$1.13M
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$91.9M – – –
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$36.3M +$20.6M +1,287,489 +210%
VVM
3
Versant Venture Management
California
$34.6M – – –
DM
4
Deerfield Management
New York
$33.1M +$5.2M +325,615 +23%
RG
5
Redmile Group
California
$27.9M +$10.2M +638,780 +78%
BlackRock
6
BlackRock
New York
$27.4M +$8.74M +547,022 +62%
Jennison Associates
7
Jennison Associates
New York
$16.2M +$8.73M +546,617 +182%
PA
8
Perceptive Advisors
New York
$13.5M +$11.2M +700,000 +9,333%
Vanguard Group
9
Vanguard Group
Pennsylvania
$13M +$6.13M +383,837 +130%
AllianceBernstein
10
AllianceBernstein
Tennessee
$12.3M +$2.45M +153,617 +32%
T. Rowe Price Associates
11
T. Rowe Price Associates
Maryland
$11.5M +$664K +41,545 +7%
RSCM
12
Rock Springs Capital Management
Maryland
$11.4M +$1.52M +95,200 +19%
CC
13
Casdin Capital
New York
$7.65M +$2.24M +140,000 +54%
Franklin Resources
14
Franklin Resources
California
$7.02M – – –
CAM
15
Cormorant Asset Management
Massachusetts
$6.19M -$1.62M -101,115 -24%
Fidelity Investments
16
Fidelity Investments
Massachusetts
$6.14M -$160K -10,000 -3%
Point72 Asset Management
17
Point72 Asset Management
Connecticut
$6.13M +$5.12M +320,393 New
DCM
18
Driehaus Capital Management
Illinois
$5.8M +$4.84M +303,212 New
EAM
19
Eventide Asset Management
Massachusetts
$4.3M – – –
State Street
20
State Street
Massachusetts
$4.23M +$2.47M +154,544 +232%
Northern Trust
21
Northern Trust
Illinois
$3.52M +$2.07M +129,681 +238%
Millennium Management
22
Millennium Management
New York
$3.47M +$1.52M +94,933 +110%
Geode Capital Management
23
Geode Capital Management
Massachusetts
$3.17M +$1.94M +121,363 +273%
SFM
24
Sphera Funds Management
Israel
$2.87M +$2.4M +150,000 New
OM
25
Opaleye Management
Massachusetts
$2.87M +$2.4M +150,000 New
1
2 3

BOLD Hedge Fund Activity: Q2 2017 in Review

70 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics, Inc (BOLD) for Q2 2017, worth a combined $409M — up 50% from $272M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new BOLD positions and 5 closed out — a net gain of 12 holders — while 37 added to existing stakes and 9 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $20.6M. The largest seller was RA Capital Management, exiting entirely with an estimated $9.07M sold.

  • 70 institutional investors held Audentes Therapeutics, Inc (BOLD) as of Q2 2017, up from 58 in Q1 2017.
  • Funds reported $409M of Audentes Therapeutics, Inc stock for Q2 2017, up 50% quarter-over-quarter.
  • 17 funds opened new Audentes Therapeutics, Inc positions in Q2 2017 and 5 closed out, a net change of +12 holders.
  • The largest Audentes Therapeutics, Inc buyer in Q2 2017 was Adage Capital Partners, an estimated $20.6M added.
  • The largest Audentes Therapeutics, Inc seller in Q2 2017 was RA Capital Management, an estimated $9.07M sold.

Based on aggregated 13F filings for Q2 2017.